These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 10512378)

  • 1. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats.
    Nakamura J; Kato K; Hamada Y; Nakayama M; Chaya S; Nakashima E; Naruse K; Kasuya Y; Mizubayashi R; Miwa K; Yasuda Y; Kamiya H; Ienaga K; Sakakibara F; Koh N; Hotta N
    Diabetes; 1999 Oct; 48(10):2090-5. PubMed ID: 10512378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes.
    Cotter MA; Jack AM; Cameron NE
    Clin Sci (Lond); 2002 Sep; 103(3):311-21. PubMed ID: 12193157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition metals and polyol pathway in the development of diabetic neuropathy in rats.
    Nakamura J; Hamada Y; Chaya S; Nakashima E; Naruse K; Kato K; Yasuda Y; Kamiya H; Sakakibara F; Koh N; Hotta N
    Diabetes Metab Res Rev; 2002; 18(5):395-402. PubMed ID: 12397582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
    Hara T; Nakamura J; Koh N; Sakakibara F; Hamada Y; Sasaki H; Naruse K; Nakashima E; Takeuchi N; Inukai S
    J Lab Clin Med; 1995 Dec; 126(6):541-7. PubMed ID: 7490513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.
    Cameron NE; Cotter MA; Dines KC; Maxfield EK; Carey F; Mirrlees DJ
    Diabetologia; 1994 Jul; 37(7):651-63. PubMed ID: 7958535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Mayer JH; Tomlinson DR
    Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased resistance to hypoxic conduction block in sciatic nerves of diabetic rats: effects of extracellular glucose concentration and of aldose reductase inhibition.
    Carrington AL; Ettlinger CB; Tomlinson DR
    J Diabetes Complications; 1994; 8(1):33-9. PubMed ID: 8167385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor, TAT.
    Nakamura J; Koh N; Sakakibara F; Hamada Y; Wakao T; Sasaki H; Mori K; Nakashima E; Naruse K; Hotta N
    Life Sci; 1997; 60(21):1847-57. PubMed ID: 9154994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
    Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K; Naruse K; Nakashima E; Sakamoto N
    J Pharmacol Exp Ther; 1996 Jan; 276(1):49-55. PubMed ID: 8558455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats.
    Nakamura J; Koh N; Sakakibara F; Hamada Y; Hara T; Sasaki H; Chaya S; Komori T; Nakashima E; Naruse K; Kato K; Takeuchi N; Kasuya Y; Hotta N
    J Pharmacol Exp Ther; 1998 Dec; 287(3):897-902. PubMed ID: 9864270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
    Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel protein kinase C-beta isoform selective inhibitor JTT-010 ameliorates both hyper- and hypoalgesia in streptozotocin- induced diabetic rats.
    Sasase T; Yamada H; Sakoda K; Imagawa N; Abe T; Ito M; Sagawa S; Tanaka M; Matsushita M
    Diabetes Obes Metab; 2005 Sep; 7(5):586-94. PubMed ID: 16050952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
    Hirata Y; Fujimori S; Okada K
    Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats.
    Matsui T; Nakamura Y; Ishikawa H; Matsuura A; Kobayashi F
    Jpn J Pharmacol; 1994 Feb; 64(2):115-24. PubMed ID: 8028228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
    J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.